<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29508857</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1759-4782</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Clinical oncology</Title>
          <ISOAbbreviation>Nat Rev Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting the PI3K pathway in cancer: are we making headway?</ArticleTitle>
        <Pagination>
          <StartPage>273</StartPage>
          <EndPage>291</EndPage>
          <MedlinePgn>273-291</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/nrclinonc.2018.28</ELocationID>
        <Abstract>
          <AbstractText>The PI3K-AKT-mTOR pathway is one of the most frequently dysregulated pathways in cancer and, consequently, more than 40 compounds that target key components of this signalling network have been tested in clinical trials involving patients with a range of different cancers. The clinical development of many of these agents, however, has not advanced to late-phase randomized trials, and the antitumour activity of those that have been evaluated in comparative prospective studies has typically been limited, or toxicities were found to be prohibitive. Nevertheless, the mTOR inhibitors temsirolimus and everolimus and the PI3K inhibitors idelalisib and copanlisib have been approved by the FDA for clinical use in the treatment of a number of different cancers. Novel compounds with greater potency and selectivity, as well as improved therapeutic indices owing to reduced risks of toxicity, are clearly required. In addition, biomarkers that are predictive of a response, such as PIK3CA mutations for inhibitors of the PI3K catalytic subunit Î± isoform, must be identified and analytically and clinically validated. Finally, considering that oncogenic activation of the PI3K-AKT-mTOR pathway often occurs alongside pro-tumorigenic aberrations in other signalling networks, rational combinations are also needed to optimize the effectiveness of treatment. Herein, we review the current experience with anticancer therapies that target the PI3K-AKT-mTOR pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Janku</LastName>
            <ForeName>Filip</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yap</LastName>
            <ForeName>Timothy A</ForeName>
            <Initials>TA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meric-Bernstam</LastName>
            <ForeName>Funda</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>UL1 TR000371</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA016672</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>03</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Rev Clin Oncol</MedlineTA>
        <NlmUniqueID>101500077</NlmUniqueID>
        <ISSNLinking>1759-4774</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011687">Purines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D052999">Quinazolinones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9HW64Q8G6G</RegistryNumber>
          <NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.137</RegistryNumber>
          <NameOfSubstance UI="D058534">Class I Phosphatidylinositol 3-Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.137</RegistryNumber>
          <NameOfSubstance UI="C484760">PIK3CA protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051058">Oncogene Protein v-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>WI6V529FZ9</RegistryNumber>
          <NameOfSubstance UI="C000589253">copanlisib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YG57I8T5M0</RegistryNumber>
          <NameOfSubstance UI="C552946">idelalisib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D058534" MajorTopicYN="N">Class I Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051058" MajorTopicYN="N">Oncogene Protein v-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052999" MajorTopicYN="N">Quinazolinones</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29508857</ArticleId>
        <ArticleId IdType="doi">10.1038/nrclinonc.2018.28</ArticleId>
        <ArticleId IdType="pii">nrclinonc.2018.28</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mol Cancer Ther. 2013 Dec;12 (12 ):2857-63</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24092809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2011 Nov 20;29(33):4452-61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22010023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2016 May 10;34(14 ):1660-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26951309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2017 Sep 1;23 (17 ):5015-5023</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28490463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2014 Nov 15;20(22):5672-85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25239610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2012 Feb 9;366(6):520-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22149876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Med. 2015 Jul;21(7):751-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26099045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2008 Oct 15;112(8):3048-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18658026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Res. 2009 Jan 1;69(1):143-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19117997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breast Cancer Res Treat. 2015 Jan;149(1):151-61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25537644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Drug Discov. 2014 Feb;13(2):140-56</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24481312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Thorac Oncol. 2014 Jul;9(7):1031-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24926548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Cancer. 2013 Sep 3;109(5):1085-92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23942080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Discov. 2017 Jul;7(7):704-715</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28331003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2014 Mar 13;370(11):1008-18</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24450858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet Oncol. 2017 Mar;18(3):297-311</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28139405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 2011 Jun 10;332(6035):1322-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21659605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2017 Oct 24;:null</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29066505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2016 Jun 15;22(12 ):2874-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26787751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncologist. 2016 Jul;21(7):787-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27286790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Oncol. 2016 Oct;27(10 ):1928-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27672108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2013 Jul 1;31(19):2485-92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23715582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer. 2016 Sep 7;:</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27603005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Res. 2013 Jan 1;73(1):276-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23066039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Cancer. 2012 Sep 25;107(7):1093-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22935583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Cancer. 2016 Apr 12;114(8):889-96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27002938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2014 Oct 9;371(15):1426-33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25295501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 2005 Feb 18;307(5712):1098-101</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15718470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sci Transl Med. 2015 Apr 15;7(283):283ra54</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25877892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Opin Pharmacol. 2015 Aug;23:98-107</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26117819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2016 Jul 7;375(1):11-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27406346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Invest New Drugs. 2015 Apr;33(2):463-71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25707361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sci Transl Med. 2015 Apr 15;7(283):283ra51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25877889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2016 Mar 5;387(10022):968-977</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26703889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Cancer. 2012 Dec;48(18):3319-27</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22921184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2013 Oct 1;19(19):5474-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24089446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer. 2015 Oct 1;121(19):3481-90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26177599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Immunol. 2003 Apr;3(4):317-30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12669022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2015 Apr 15;21(8):1888-95</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25652454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Drug Discov. 2009 Aug;8(8):627-44</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19644473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Discov. 2012 May;2(5):425-33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22588880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Cancer. 2015 Jan;15(1):7-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25533673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet Oncol. 2018 Jan;19(1):87-100</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29223745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nature. 2016 Nov 17;539(7629):443-447</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27828943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet Oncol. 2013 Feb;14 (2):134-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23261356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell Rep. 2014 Jan 30;6(2):377-87</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24440717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Colorectal Cancer. 2016 Dec;15(4):337-344.e2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27118441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Cancer. 2009 Aug;9(8):550-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19629070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2017 Jun 1;376(22):2109-2121</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28445112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2012 Oct 15;18(20):5816-28</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22932669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2010 Aug 26;363(9):809-19</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20818844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Invest. 2010 Aug;120(8):2858-66</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20664172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Invest New Drugs. 2014 Dec;32(6):1197-203</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24916771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2017 Jan 1;23 (1):26-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27126994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2015 Nov 5;373(19):1803-13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26406148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cancer Ther. 2011 Mar;10 (3):558-65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21216929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nature. 2008 Aug 7;454(7205):776-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18594509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2012 Jan 20;30(3):282-90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22162589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Hematol. 2016 Jun;91(4):400-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26800393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oral Oncol. 2015 Apr;51(4):383-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25593016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2014 Dec 1;20(23):5908-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25231405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2007 May 31;356(22):2271-81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17538086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2015 Jul 15;21(14):3160-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25840972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mol Cancer Ther. 2012 Sep;11(9):2062-71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22723336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Discov. 2017 Jan;7(1):102-113</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27872130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet Oncol. 2016 Jun;17 (6):811-821</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27155741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2015 Apr 1;21(7):1525-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25645861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Med. 2008 Dec;14(12):1351-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19029981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2018 Jan 1;24(1):22-32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29051322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet Oncol. 2017 Oct;18(10 ):1360-1372</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28800861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer. 2018 Jan 15;124(2):315-324</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28976556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Oncol. 2017 Feb 1;28(2):313-320</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27803006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Immunol. 2008 May;38(5):1215-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18412166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Cancer. 2017 May;76:36-44</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28282611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2013 Feb 1;19(3):657-67</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23251002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2017 Dec 10;35(35):3898-3905</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28976790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Discov. 2015 Dec;5(12):1262-70</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26370156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Cancer. 2017 Jan 15;140(2):449-459</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27699769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2013 Jan 12;381(9861):125-32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23158522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2016 Aug 1;:</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27480147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2017 Jul 15;23 (14 ):3520-3528</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28031425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Discov. 2017 Jun;7(6):610-619</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28363909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Ther. 2014 May;142(2):164-75</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24333502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS One. 2015 Oct 15;10(10):e0140479</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26469692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2018 Feb 5;:JCO2017727107</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29401002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2017 Jul 10;35(20):2251-2259</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28489509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Treat Rev. 2017 Sep;59:93-101</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28779636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Cancer. 2006 Sep;6(9):729-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16915295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2015 Feb 15;21(4):730-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25500057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2011 Feb 10;364(6):514-23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21306238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2010 Nov 4;363(19):1801-11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21047224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncologist. 2015 Mar;20(3):245-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25669662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oncologist. 2017 Apr;22(4):377-e37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28275119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2008 Aug 9;372(9637):449-56</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18653228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet Oncol. 2017 Jul;18(7):904-916</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28576675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Oncol. 2015 Jul;26(7):1346-52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25878190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Invest New Drugs. 2014 Jun;32(3):510-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24395457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Oncol. 2012 Sep;23 (9):2399-408</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22357447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cell. 2017 Mar 9;168(6):960-976</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28283069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 2011 Jun 10;332(6035):1317-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21659604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2015 Aug 20;373(8):726-36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26287849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gynecol Oncol. 2015 Feb;136(2):246-53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25528496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Oncol. 2016 Nov;27(11):2059-2066</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27573562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2014 Jan 1;20(1):233-45</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24166903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2014 Mar 13;370(11):997-1007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24450857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Clin Oncol. 2013 Mar;10(3):143-53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23400000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Natl Cancer Inst. 2015 Feb 16;107(3):null</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25688104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2012 Aug 1;18(15):4173-82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22693357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2011 Jul 1;29(19):e572-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21482991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Science. 2012 Oct 12;338(6104):221</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22923433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2016 May 15;22(10 ):2445-2452</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26831717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>PLoS One. 2011;6(7):e22769</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21829508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2012 Mar 10;30(8):777-82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22271473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Cancer Res. 2017 Oct 1;23 (19):5981-5992</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28645941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nat Rev Clin Oncol. 2011 May 17;8(9):528-39</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21587219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Discov. 2014 May;4(5):554-63</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24631838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2016 Jul 14;128(2):195-203</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27247136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blood. 2016 May 19;127(20):2411-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26968534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nature. 2015 Feb 12;518(7538):240-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25409150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N Engl J Med. 2016 Jul 7;375(1):23-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27406347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Oncol. 2011 Dec 10;29(35):4688-95</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22025163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nature. 2012 Jan 26;483(7387):100-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22281684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2013 Mar 9;381(9869):817-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23312829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet Oncol. 2016 Jul;17 (7):917-927</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27279544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuro Oncol. 2015 Sep;17(9):1270-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25605819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ann Oncol. 2015 Mar;26(3):556-61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25524478</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
